Le Lézard
Classified in: Health
Subject: HEALTH

Alberta Cancer Foundation announces $10 million in support of cellular therapy excellence


EDMONTON, Alberta, Oct. 25, 2023 (GLOBE NEWSWIRE) -- At a recent BioAlberta event in Edmonton, the Alberta Cancer Foundation announced a major boost for the province's cellular therapy program ? a revolutionary treatment for cancer that has the potential to dramatically improve survival rates for hard-to-treat cancers. The nearly $10 million commitment will bring life-saving treatment to more Albertans sooner and further the province's reputation as a leader in cancer research.

"Cellular therapy may represent the most significant progress in curing some treatment-resistant cancers in decades. And it's happening right here, in Alberta," said Wendy Beauchesne, CEO of the Alberta Cancer Foundation. Cellular therapy harnesses the power of a patient's own immune system by engineering ?super cells' to attack and kill cancer cells and tumours within their own body.

In 2018, the Alberta Cancer Foundation and the Government of Alberta kickstarted the Alberta Cellular Therapy Program, including a made-in-Alberta clinical trial led by the renowned Dr. Michael Chu. To date, this remarkable clinical trial has increased the quality of life for 25 patients at a much lower cost than commercial alternatives. Most importantly, many of these patients have gone from being palliative to being cancer-free. This $10 million boost will enable more patients to access these clinical trials, drive down the cost of these treatments and help build a Health Canada-approved, in-house lab for manufacturing CAR T cell therapies ? bringing them closer to patients in the Cross Cancer Institute.

"Imagine the potential this holds for cancer patients for whom surgery, radiation and chemotherapy simply doesn't work," said Brenda Hubley, Chief Program Officer at Cancer Care Alberta. "This funding announcement ? made possible through the generous support of donors ? starts to bring a new future into focus for those cancer patients desperate for good news."

Both Hubley and Beauchesne agree that there is a unique opportunity for Alberta to build on its strengths in immunotherapy research, point-of-care manufacturing, clinical trial delivery, commercial translation, and cellular therapy services ? building a true ?best in class' centre of excellence for cellular therapy. "The last 20 years have seen incredible advances in cancer care and treatment, and Alberta has been right there at the very front," said Beauchesne. "This $10 million sets us up for the next 20 years of innovation and hope for Albertans," added Hubley.

Media contact:

Ryan Kelly
Vice President of Communications and Community Partnerships
Alberta Cancer Foundation
1-780-220-8791
[email protected]



These press releases may also interest you

at 12:00
ATLATL Scientific and Miltenyi Biotec are celebrating a landmark five-year partnership, marking a journey of collaboration and innovation in the biotech sector. With a strong foundation laid over the years, this partnership has flourished into a...

at 12:00
Twenty-four states have barred access to gender-affirming care (GAC) for transgender and gender diverse (TGD) youth, while...

at 12:00
Soterix Medical Inc., the global leader in non-invasive brain stimulation and synergistic monitoring technologies, announced the launch of MxN-GO EEG, a combined High Definition transcranial Electrical Stimulation (HD-tES) and EEG system with a...

at 11:45
Verde Environmental Technologies, Inc.'s Deterra® Drug Deactivation and Disposal System was named a winner of a Silver Stevie® Award in the category "Products in the Area of Sustainability & Climate Protection" in The 22nd Annual American Business...

at 11:31
Denovo Biopharma LLC (Denovo), a pioneer in applying precision medicine to the development of innovative therapies, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded a $11.8M grant for further development of...

at 11:30
North American Company for Life and Health Insurance® (North American), a member company of Sammons® Financial Group and one of the largest issuers of fixed index annuities (FIAs) in the U.S.,1 is once again expanding its partnership with Annexus, a...



News published on and distributed by: